CN110934758A - Application of high-purity astaxanthin extracted from Haematococcus pluvialis in cosmetics of different dosage forms - Google Patents

Application of high-purity astaxanthin extracted from Haematococcus pluvialis in cosmetics of different dosage forms Download PDF

Info

Publication number
CN110934758A
CN110934758A CN201811107529.8A CN201811107529A CN110934758A CN 110934758 A CN110934758 A CN 110934758A CN 201811107529 A CN201811107529 A CN 201811107529A CN 110934758 A CN110934758 A CN 110934758A
Authority
CN
China
Prior art keywords
astaxanthin
oil
haematococcus pluvialis
water
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811107529.8A
Other languages
Chinese (zh)
Inventor
尹烁
吴复跃
何振东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI SHANGRUI BIOLOGICAL PHARMACEUTICAL Co Ltd
Shanghai Rui Tai Biological Polytron Technologies Inc
Original Assignee
SHANGHAI SHANGRUI BIOLOGICAL PHARMACEUTICAL Co Ltd
Shanghai Rui Tai Biological Polytron Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI SHANGRUI BIOLOGICAL PHARMACEUTICAL Co Ltd, Shanghai Rui Tai Biological Polytron Technologies Inc filed Critical SHANGHAI SHANGRUI BIOLOGICAL PHARMACEUTICAL Co Ltd
Priority to CN201811107529.8A priority Critical patent/CN110934758A/en
Publication of CN110934758A publication Critical patent/CN110934758A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)

Abstract

The invention relates to application of high-purity astaxanthin extracted from haematococcus pluvialis in cosmetics in different formulations. The astaxanthin used by the invention is derived from haematococcus pluvialis and has a full-levorotatory structure. The natural astaxanthin is applied to various formulations of skin care products including jelly type products, toner, essence, facial masks, cream type products and the like in a solubilizing mode or a micro-emulsifying mode of an oil-in-water type emulsifier, so that the application of the natural astaxanthin in medical beauty products and daily skin care cosmetics is expanded.

Description

Application of high-purity astaxanthin extracted from Haematococcus pluvialis in cosmetics of different dosage forms
Technical Field
The invention relates to the field of cosmetics, in particular to application of high-purity astaxanthin extracted from haematococcus pluvialis in cosmetics in different formulations.
Background
Astaxanthin extracted from haematococcus pluvialis is one of the strongest natural antioxidants in the world, can effectively eliminate oxygen free radicals in cells, enhances the cell regeneration capacity, maintains the organism balance, reduces the accumulation of aged cells, protects the cells and DNA from inside to outside, thereby protecting the skin health, promoting the hair growth, resisting aging, relieving sports fatigue and the like. The antioxidant activity of the astaxanthin is 6000 times of that of vitamin C and 1000 times of that of vitamin E, and the astaxanthin is the only carotenoid which can pass through a blood brain barrier.
The skin is composed of three layers: epidermis layer, dermis layer, subcutaneous fat layer. The dermis contains collagen, elastin and other fibers that form the skeleton supporting the skin, and these elements are susceptible to damage by UVA and UVB. Wherein the UVA wavelength is relatively long, can reach the dermis layer, mainly damages collagen and elastin, and the disappearance of the skeleton supporting the skin can cause the uneven collapse of the skin, and finally the formation of wrinkles. UVB acts primarily on the epidermis, leading to sunburn or melanin deposition, formation of spots or darkening of the skin. The astaxanthin has a unique molecular structure, the absorption peak value of the astaxanthin is about 470nm and is close to UVA (380nm-420nm), so that a large amount of UVA can be absorbed by trace astaxanthin, the damage of ultraviolet rays to the skin is reduced, and the skin damaged by ultraviolet ray burning can be quickly recovered. However, a large amount of data show that the natural astaxanthin is extremely insoluble in water and soluble in oil due to the special structure, so that the application of the natural astaxanthin in aqueous cosmetics is limited.
Chinese patent CN103772451A discloses an astaxanthin derivative, which is prepared by adding a compound providing succinate radical into astaxanthin or an organic solution in which astaxanthin is dissolved for heating reaction, adding water after the reaction is finished, stirring, standing for precipitation, and collecting precipitate; then adding glycosyl molecules into the solution of the compound dissolved with the precipitate, and connecting the glycosyl molecules through esterification reaction. The prepared astaxanthin disuccinate derivative can be used for processing and coloring in industries such as pharmaceuticals, cosmetics and the like; can be used as functional component for developing health food. The patent develops a water-soluble astaxanthin derivative, and is further applicable to aqueous cosmetics. In this patent, astaxanthin is structurally modified to become an astaxanthin derivative to thereby change the solubility properties of astaxanthin. Therefore, the astaxanthin derivative is added to the aqueous cosmetics.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide the application of high-purity astaxanthin extracted from haematococcus pluvialis in cosmetics in different formulations.
The natural astaxanthin is applied to various formulations of skin care products including jelly type products, toner, essence, facial masks, cream type products and the like in a solubilizing mode or a micro-emulsifying mode of an oil-in-water type emulsifier, so that the application of the natural astaxanthin in medical beauty products and daily skin care cosmetics is expanded.
The purpose of the invention can be realized by the following technical scheme:
the application of high-purity astaxanthin extracted from haematococcus pluvialis in the water-based cosmetics comprises the following steps:
(1) mixing astaxanthin and solubilizer for solubilization, and stirring until the astaxanthin and solubilizer are completely dissolved to obtain solution A;
(2) mixing the water phase substances to obtain a solution B;
(3) adding the solution A into the solution B, stirring uniformly, and stirring fully to dissolve to obtain aqueous composition, namely the aqueous cosmetic.
In one embodiment of the present invention, the astaxanthin is mixed with the solubilizer in a manner that:
dissolving astaxanthin in solubilizer, adding deionized water, and stirring to dissolve completely; or the like, or, alternatively,
adding the astaxanthin into deionized water, adding the solubilizer, and stirring until the astaxanthin is completely dissolved.
It should be noted that, in the present invention, the solution obtained by first solubilizing and then dissolving astaxanthin in water and then solubilizing astaxanthin in water is different in stability and transparency of the solution, according to the experimental study of the present invention, the stability and transparency of the solution obtained by dissolving astaxanthin in the solubilizing agent and then adding deionized water are better, which is a more preferable technical solution.
In one embodiment of the invention, the solubilizing agent comprises a polyol comprising butylene glycol, propylene glycol, pentylene glycol, octylene glycol, hexylene glycol, and the like, and hydrogenated castor oil.
The polyhydric alcohol has effects of moisturizing and solubilizing besides solubilizing effect.
In one embodiment of the invention, the aqueous phase material is selected from one or more of the following:
sodium hyaluronate, β -dextran, polyglutamic acid, trehalose, sodium carboxymethylcellulose, sodium carboxyethyl cellulose, cocol ether-7/PPG-1-PEG-9, lauryl glycol ether/PEG-40 sodium ricinoleate, chitin, chitosan, collagen, allantoin, nicotinamide, xanthan gum, tremella polysaccharide and the like.
In one embodiment of the present invention, the aqueous phase material comprises at least sodium hyaluronate and collagen.
The invention also provides application of the high-purity astaxanthin extracted from haematococcus pluvialis in cream type cosmetics, which comprises the following steps:
(1) mixing astaxanthin with oil phase substances to obtain a solution C;
(2) mixing the water phase substances to obtain a solution B;
(3) adding the solution B into the solution C, stirring, homogenizing, and emulsifying to obtain oil-in-water cream composition, i.e. cream type cosmetic.
In one embodiment of the present invention, the oil phase material is selected from one or more of the following materials:
isooctyl palmitate, wheat germ oil, white oil, lanolin, petrolatum, horse oil, beeswax, squalane, jojoba oil, sunflower seed oil, macadamia nut oil, caprylic/capric triglyceride, dimethicone, ayurvedic seed fat, olive oil, acalypha australis seed oil, tocopheryl acetate, sweet almond oil, mandarin orange peel oil, hydrogenated vegetable oil, or cetyl ethylhexanoate;
some of the above oil phase materials act as oil-in-water type emulsifiers.
In one embodiment of the invention, the aqueous phase material is selected from one or more of the following:
sodium hyaluronate, β -dextran, polyglutamic acid, trehalose, sodium carboxymethylcellulose, sodium carboxyethyl cellulose, cocol ether-7/PPG-1-PEG-9, lauryl glycol ether/PEG-40 sodium ricinoleate, chitin, chitosan, collagen, allantoin, nicotinamide, xanthan gum, tremella polysaccharide and the like.
In one embodiment of the present invention, the aqueous phase material comprises at least sodium hyaluronate and collagen.
In one embodiment of the present invention, the mass concentration of astaxanthin in the aqueous cosmetic or cream cosmetic is 0.01 to 10%, preferably 0.01 to 1%.
In the invention, the astaxanthin is derived from haematococcus pluvialis, is levorotatory trans-lipidated astaxanthin and has a full-levorotatory structure.
When the astaxanthin is applied to the cream type cosmetics, the obtained product is of an oil-in-water type, so that the cream type products are added in a mode of adding a water phase substance to an oil phase substance, and a stable oil-in-water system is easier to form. The oil-in-water product has an oil phase, so that the cream product does not need to solubilize the astaxanthin, only needs to treat the astaxanthin as an oil phase raw material, and for the water-type product, the astaxanthin needs to be firstly compatibilized and then is subjected to water dissolving treatment.
The water-based cosmetic comprises gel, toner, essence, facial mask, stock solution, emulsion and the like.
The cream type cosmetics of the invention mainly comprise cream, cream products and the like.
In the present invention, the above-mentioned aqueous phase substance or oil phase substance includes most of the commonly used cosmetic additives, which have respective properties or uses, and are not further distinguished in the present invention, but are distinguished only by the aqueous phase substance or oil phase substance.
In addition to the above-mentioned substances related to the aqueous phase substance or the oil phase substance, other cosmetic additives are classified into aqueous phase substances or oil phase substances according to their properties when the present invention is applied, and are further used in accordance with the present invention.
In addition, in the technical scheme of the invention, the oil phase substance or the water phase substance can be added in batches, and the astaxanthin can be dissolved by solubilization or dissolution with the oil phase substance.
In addition, the mixing method, the mixing temperature, and the formulation of each component in the present invention are performed by referring to the conventional technical means of general cosmetics.
Compared with the prior art, the invention has the following advantages: the natural haematococcus pluvialis applied by the invention has higher purity and better biological activity. The natural astaxanthin is applied to various formulations of skin care products in a solubilizing mode or a micro-emulsifying mode of an oil-in-water type emulsifier, so that the application of the natural astaxanthin in medical beauty products and daily skin care cosmetics is expanded. In addition, the collagen applied in each dosage form is full-length collagen macromolecules extracted from animal tissues, has the functions of bioactivity and guided repair, the sodium hyaluronate applied is a medicinal-grade synthetic raw material, and the sodium hyaluronate and the natural astaxanthin can improve the functions of moisturizing and lubricating the skin of the hyaluronic acid and exert the function of guided tissue repair of the collagen, fully protect the chemical structure of the natural astaxanthin and fully exert the antioxidant effect of the natural astaxanthin, and show greater advantages in the field of development of medical beauty products. The application fields of the invention include the fields of food, biomedicine, medical apparatus and instruments, tissue engineering, cosmetics and the like.
Detailed Description
The present invention will be described in detail with reference to specific examples.
Example 1
A skin care gel formulation comprises, by weight, 0.5% of natural astaxanthin, 1% of hydrogenated castor oil complex, 3% of sodium hyaluronate (molecular weight of 30-300 kilodaltons), 5% of nicotinamide, 1% of polyglutamic acid, 3% of trehalose, 1% of collagen, 0.5% of caprylyl glycol/hexylene glycol, 5% of pentanediol, 6% of butanediol, 1% of glycerol, 0.5% of xanthan gum, and the balance of deionized water.
Example 2
A skin care gel formulation comprises, by weight, 1% of natural astaxanthin, 2% of hydrogenated castor oil composite component, 1% of sodium hyaluronate (molecular weight of 30-300 ten thousand daltons), 3% of nicotinamide, 0.5% of polyglutamic acid, 3% of trehalose, 1% of tremella polysaccharide, 0.7% of collagen, 0.5% of caprylyl glycol/hexylene glycol, 3% of pentanediol, 6% of butanediol, 1% of glycerol, 0.3% of xanthan gum, and the balance of deionized water.
Example 3
A skin care gel formulation comprises, by weight, 0.3% of natural astaxanthin, 1% of hydrogenated castor oil composite component, 0.5% of sodium hyaluronate (molecular weight of 30-300 ten thousand daltons), 2% of nicotinamide, 1% of polyglutamic acid, 10% of β -dextran, 2% of tremella polysaccharide, 0.3% of collagen, 0.5% of caprylyl glycol/hexylene glycol, 5% of pentanediol, 6% of butanediol, 1% of glycerol, 0.1% of xanthan gum, and the balance of deionized water.
Example 4
A liquid formulation for skin care comprises, by weight, 0.5% of natural astacin, 1% of a hydrogenated castor oil complex, 0.1% of sodium hyaluronate (molecular weight of 30-300 ten thousand daltons), 2% of nicotinamide, 0.5% of polyglutamic acid, 3% of β -dextran, 0.1% of collagen, 0.5% of caprylyl glycol/hexylene glycol, 3% of pentanediol, 6% of butanediol, 0.5% of glycerin, 0.05% of xanthan gum, and the balance deionized water.
Example 5
A liquid preparation for skin care comprises aqua, essence, facial mask, stock solution, etc. According to the weight percentage, the liquid preparation comprises 1% of natural astaxanthin, 2% of hydrogenated castor oil composite component, 0.2% of sodium hyaluronate (the molecular weight is 30-300 ten thousand daltons), 3% of nicotinamide, 0.3% of polyglutamic acid, 0.5% of trehalose, 1% of tremella polysaccharide, 0.2% of collagen, 0.5% of octyl glycol/hexanediol, 2% of pentanediol, 6% of butanediol, 1% of glycerol, 0.1% of xanthan gum and the balance of deionized water.
Example 6
A liquid formulation for skin care comprises, by weight, 0.2% of natural astacin, 0.5% of a hydrogenated castor oil composite component, 0.2% of sodium hyaluronate (molecular weight of 30-300 ten thousand daltons), 2% of nicotinamide, 0.2% of polyglutamic acid, 1% of β -dextran, 0.5% of tremella polysaccharide, 1% of hydrolyzed collagen, 0.5% of caprylyl glycol/hexylene glycol, 4% of pentanediol, 6% of butanediol, 0.5% of glycerin, 0.05% of xanthan gum, and the balance of deionized water.
Examples 1-6 above all show the use of high purity astaxanthin extracted from Haematococcus pluvialis in aqueous cosmetic formulations, and examples 1-6 above show the formulation of high purity astaxanthin extracted from Haematococcus pluvialis in aqueous cosmetic formulations. The preparation method of the water-based cosmetic comprises the following steps:
(1) dissolving astaxanthin in a solubilizer in the formula, adding deionized water, and stirring until the astaxanthin is completely dissolved to obtain a solution A;
(2) then mixing the water phase substances in the formula to obtain a solution B;
(3) adding the solution A into the solution B, stirring uniformly, and stirring fully to dissolve to obtain aqueous composition, namely the aqueous cosmetic.
In examples 1 to 6, the oil phase material or the water phase material may be added in a batch manner, as long as the astaxanthin is solubilized and dissolved or dissolved with the oil phase material.
In the above examples 1 to 6, the mixing manner and the mixing temperature were carried out by referring to the conventional technical means of general cosmetics.
Example 7
The skin care cream comprises, by weight, 0.5% of natural astaxanthin, 3% of sunflower seed oil, 6% of caprylic/capric triglyceride, 5% of cetyl ethylhexanoate, 2% of isooctyl palmitate, 2% of sodium acrylate copolymer/lecithin compound, 0.2% of sodium hyaluronate (molecular weight of 30-300 ten thousand daltons), 1% of nicotinamide, 1% of micromolecule β -dextran, 1% of hydrolyzed collagen, 0.5% of caprylyl glycol/hexanediol, 0.5% of p-hydroxyacetophenone, 6% of butanediol, 0.5% of glycerol and the balance of deionized water.
Example 8
The skin care cream comprises, by weight, 0.5% of natural astaxanthin, 5% of macadamia nut seed oil, 5% of caprylic/capric triglyceride, 4% of cetyl ethylhexanoate, 3% of jojoba wax, 3% of sodium acrylate copolymer/lecithin compound, 0.5% of sodium hyaluronate (molecular weight of 30-300 ten thousand daltons), 2% of nicotinamide, 2% of β -dextran, 0.5% of collagen, 0.5% of caprylyl glycol/hexylene glycol, 0.5% of p-hydroxyacetophenone, 6% of butylene glycol, 0.5% of glycerin, and the balance of deionized water.
Example 9
A skin care ointment dosage form comprises ointment, cream, lotion, etc. According to the weight percentage, the paste comprises 0.5% of natural astaxanthin, 3% of olive oil, 3% of macadamia nut seed oil, 5% of caprylic acid/capric acid triglyceride, 3% of cetyl ethyl hexanoate, 2% of polydimethylsiloxane, 3% of sweet almond oil/red tangerine peel oil/hydrogenated vegetable oil, 1.5% of sodium acrylate copolymer/lecithin compound, 0.3% of sodium hyaluronate (with the molecular weight of 30-300 ten thousand daltons), 1% of nicotinamide, 2% of tremella polysaccharide, 0.3% of collagen, 0.5% of caprylyl glycol/hexanediol, 0.5% of p-hydroxyacetophenone, 6% of butanediol, 1% of glycerol and the balance of deionized water.
Examples 7 to 9 above all show the use of high-purity astaxanthin derived from Haematococcus pluvialis in cream-type cosmetics, and examples 7 to 9 above show the formulations of high-purity astaxanthin derived from Haematococcus pluvialis in cream-type cosmetics. The preparation method of the cream type cosmetic comprises the following steps:
(1) dissolving astaxanthin in an oil phase substance in the formula to obtain a solution C;
(2) then mixing the water phase substances in the formula to obtain a solution B;
(3) adding the solution B into the solution C, stirring, homogenizing, and emulsifying to obtain oil-in-water cream composition, i.e. cream type cosmetic.
In examples 7 to 9, the oil phase material or the water phase material may be added in a batch manner, as long as the astaxanthin is solubilized and dissolved or dissolved with the oil phase material.
In the above examples 7 to 9, the mixing manner and the mixing temperature were carried out by referring to the conventional technical means of general cosmetics.
The embodiments described above are described to facilitate an understanding and use of the invention by those skilled in the art. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above embodiments, and those skilled in the art should make improvements and modifications within the scope of the present invention based on the disclosure of the present invention.

Claims (10)

1. The application of the high-purity astaxanthin extracted from haematococcus pluvialis in the water-based cosmetics is characterized by comprising the following steps:
(1) mixing astaxanthin and solubilizer for solubilization, and stirring until the astaxanthin and solubilizer are completely dissolved to obtain solution A;
(2) mixing the water phase substances to obtain a solution B;
(3) adding the solution A into the solution B, stirring uniformly, and stirring fully to dissolve to obtain aqueous composition, namely the aqueous cosmetic.
2. The use of high purity astaxanthin extracted from Haematococcus pluvialis as claimed in claim 1 in cosmetic water preparations, wherein the astaxanthin is mixed with a solubilizer in such a manner that:
dissolving astaxanthin in solubilizer, adding deionized water, and stirring to dissolve completely; or the like, or, alternatively,
adding the astaxanthin into deionized water, adding the solubilizer, and stirring until the astaxanthin is completely dissolved.
3. The use of high purity astaxanthin extracted from Haematococcus pluvialis as claimed in claim 1 in cosmetic water formulations, wherein said solubilizing agent comprises polyhydric alcohol including butylene glycol, propylene glycol, pentylene glycol, octylene glycol, hexylene glycol, and hydrogenated castor oil.
4. The use of high purity astaxanthin extracted from Haematococcus pluvialis as claimed in claim 1 in cosmetic water-based preparations, wherein the water-phase material is selected from one or more of the following materials:
sodium hyaluronate, β -dextran, polyglutamic acid, trehalose, sodium carboxymethylcellulose, sodium carboxyethyl cellulose, cocol ether-7/PPG-1-PEG-9, lauryl glycol ether/PEG-40 sodium ricinoleate, chitin, chitosan, collagen, allantoin, nicotinamide, xanthan gum and tremella polysaccharide.
5. The use of high purity astaxanthin extracted from Haematococcus pluvialis as claimed in claim 4, wherein the aqueous phase comprises at least sodium hyaluronate and collagen.
6. The application of the high-purity astaxanthin extracted from haematococcus pluvialis in cream cosmetics is characterized by comprising the following steps:
(1) mixing astaxanthin with oil phase substances to obtain a solution C;
(2) mixing the water phase substances to obtain a solution B;
(3) adding the solution B into the solution C, stirring, homogenizing, and emulsifying to obtain oil-in-water cream composition, i.e. cream type cosmetic.
7. The use of high purity astaxanthin extracted from Haematococcus pluvialis as claimed in claim 6, wherein the oil phase material is selected from one or more of the following materials:
isooctyl palmitate, wheat germ oil, white oil, lanolin, petrolatum, horse oil, beeswax, squalane, jojoba oil, sunflower seed oil, macadamia nut oil, caprylic/capric triglyceride, dimethicone, sabia indica seed oil, olive fruit oil, acanga oil, tocopheryl acetate, sweet almond oil, mandarin orange peel oil, hydrogenated vegetable oil, or cetyl ethylhexanoate.
8. The use of high purity astaxanthin extracted from Haematococcus pluvialis as claimed in claim 6, wherein the water phase material is selected from one or more of the following materials:
sodium hyaluronate, β -dextran, polyglutamic acid, trehalose, sodium carboxymethylcellulose, sodium carboxyethyl cellulose, cocol ether-7/PPG-1-PEG-9, lauryl glycol ether/PEG-40 sodium ricinoleate, chitin, chitosan, collagen, allantoin, nicotinamide, xanthan gum and tremella polysaccharide.
9. The use of high purity astaxanthin extracted from Haematococcus pluvialis as claimed in claim 8, wherein the aqueous phase comprises at least sodium hyaluronate and collagen.
10. The use according to claim 1 or 6, wherein the mass concentration of astaxanthin in the aqueous or cream cosmetic is 0.01 to 10%, preferably 0.01 to 1%.
CN201811107529.8A 2018-09-21 2018-09-21 Application of high-purity astaxanthin extracted from Haematococcus pluvialis in cosmetics of different dosage forms Pending CN110934758A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811107529.8A CN110934758A (en) 2018-09-21 2018-09-21 Application of high-purity astaxanthin extracted from Haematococcus pluvialis in cosmetics of different dosage forms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811107529.8A CN110934758A (en) 2018-09-21 2018-09-21 Application of high-purity astaxanthin extracted from Haematococcus pluvialis in cosmetics of different dosage forms

Publications (1)

Publication Number Publication Date
CN110934758A true CN110934758A (en) 2020-03-31

Family

ID=69905550

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811107529.8A Pending CN110934758A (en) 2018-09-21 2018-09-21 Application of high-purity astaxanthin extracted from Haematococcus pluvialis in cosmetics of different dosage forms

Country Status (1)

Country Link
CN (1) CN110934758A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101005768A (en) * 2004-08-31 2007-07-25 阿克佐诺贝尔股份有限公司 Method for pigment solubilisation, a pigment composition and its use
CN104135994A (en) * 2012-02-24 2014-11-05 富士胶片株式会社 Lycopene-containing composition
CN105582001A (en) * 2015-12-25 2016-05-18 南京泛成生物化工有限公司 Astaxanthin composition, preparation and preparation method of composition
CN106176266A (en) * 2014-08-25 2016-12-07 富士胶片株式会社 Cosmetic preparation
CN108324609A (en) * 2018-03-13 2018-07-27 云南爱尔康生物技术有限公司 A kind of moisture retention water of astaxanthin-containing and preparation method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101005768A (en) * 2004-08-31 2007-07-25 阿克佐诺贝尔股份有限公司 Method for pigment solubilisation, a pigment composition and its use
CN104135994A (en) * 2012-02-24 2014-11-05 富士胶片株式会社 Lycopene-containing composition
CN106176266A (en) * 2014-08-25 2016-12-07 富士胶片株式会社 Cosmetic preparation
CN105582001A (en) * 2015-12-25 2016-05-18 南京泛成生物化工有限公司 Astaxanthin composition, preparation and preparation method of composition
CN108324609A (en) * 2018-03-13 2018-07-27 云南爱尔康生物技术有限公司 A kind of moisture retention water of astaxanthin-containing and preparation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
周庆新等: "环境因素对红球藻虾青素酯微乳液稳定性的影响", 《食品科技》 *
惠伯棣: "《类胡萝卜素化学及生物化学》", 31 January 2005, 中国轻工业出版社 *
高俊全等: "《虾青素：健康新世纪的奥秘》", 31 July 2013, 中国医药科技出版社 *

Similar Documents

Publication Publication Date Title
CA2444282C (en) Preparation for hair and/or scalp
MXPA04000002A (en) Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue.
KR20130088912A (en) Skin external composition containing tangeretin and egcg
KR20130069512A (en) Skin external composition comprising tangeretin
JPH08208451A (en) Skin-beautifying agent mixed with extract of crude medicine from plant
JP2008260721A (en) External preparation for skin
CN109464308B (en) Essential oil composition with blue light resisting and skin caring effects and application thereof
JP2002121112A (en) Skin care preparation
CN106726795A (en) A kind of multifunctional sun cream and preparation method thereof
JP2001158728A (en) Agent for promoting production of hyaluronic acid and skin preparation for external use
EP2100592B1 (en) Cosmetic product with anti-aging effect
CN115887336A (en) Skin-care composition and cosmetic
CN110934758A (en) Application of high-purity astaxanthin extracted from Haematococcus pluvialis in cosmetics of different dosage forms
JP2004331602A (en) Skin care preparation for external use
JP6679270B2 (en) Topical composition for antifolliculitis
JP2000096050A (en) Promoter for production of hyaluronic acid
CN115887280A (en) Composition of retinol derivatives and application thereof
JP3119622B2 (en) Cosmetics
JPH10158143A (en) Photo-aging prevention and improving agent and skin cosmetic
JPH11171784A (en) External preparation for skin
JP2005029494A (en) Melanocyte proliferation inhibitor and cosmetic containing the same
JP2011046646A (en) Antioxidant and skin external preparation
CA2382833A1 (en) Topical urea composition
JP5937465B2 (en) Collagen production promoter, fibroblast proliferation promoter, wrinkle improving agent and skin external preparation
JP2004352628A (en) External preparation for skin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200331